Mocetinostat: all 22 studies that test it
Page 1 of 1. Open to participants first (0), then studies with results posted, then the rest; newest registration first within each.
- Phase 2 Study of Glesatinib, Sitravatinib or Mocetinostat in Combination With Nivolumab in Non-Small Cell Lung CancerTerminatedNCT02954991Phase 2Results posted
- Phase 1/2 Study of Mocetinostat and Durvalumab in Patients With Advanced Solid Tumors and NSCLCTerminatedNCT02805660Phase 1/2Results posted
- Mocetinostat (MGCD0103) Plus Brentuximab Vedotin (SGN-35) in Patients With Relapsed or Refractory Hodgkin LymphomaCompletedNCT02429375Phase 1/2Results posted
- SARC018: A Study of Mocetinostat and Gemcitabine in Patients With Metastatic LeiomyosarcomaCompletedNCT02303262Phase 2Results posted
- Study of Mocetinostat in Selected Patients With Mutations of Acetyltransferase Genes in Relapsed and Refractory Diffuse Large B-Cell Lymphoma and Follicular LymphomaTerminatedNCT02282358Phase 1/2Results posted
- Mocetinostat With Vinorelbine in Children, Adolescents & Young Adults With Refractory and/or Recurrent RhabdomyosarcomaActive, not recruitingNCT04299113Phase 1
- Pembrolizumab (Immunotherapy Drug) in Combination With Guadecitabine and Mocetinostat (Epigenetic Drugs) for Patients With Advanced Lung Cancer.Active, not recruitingNCT03220477Phase 1
- Pre-operative Mocetinostat (MGCD0103) and Durvalumab (MEDI4736) (PRIMED) for Squamous Cell Carcinoma of the Oral CavityWithdrawnNCT02993991Phase 1
- Study of Mocetinostat in Patients With Urothelial Carcinoma Having Inactivating Alterations of Specific GenesCompletedNCT02236195Phase 2
- Safety Study of Mocetinostat in Combination With Azacitidine in Subjects With MDSCompletedNCT02018926Phase 1/2
- Phase 2 Study of Azacitidine (Vidaza) vs MGCD0103 vs Combination in Elderly Subjects With Newly Diagnosed Acute Myeloid Leukemia (AML) or Myelodysplastic Syndrome (MDS)TerminatedNCT00666497Phase 2
- MGCD0103 Administered in Combination With Azacitidine (Vidaza®) to Subjects With Relapsed or Refractory Hodgkin or Non-Hodgkin LymphomaTerminatedNCT00543582Phase 2
- Study to Evaluate Combination Treatment of MGCD0103 and Docetaxel (Taxotere®) for Subjects With Advanced Cancer TumorsTerminatedNCT00511576Phase 1
- A Phase II Study of MGCD0103 (MG-0103) in Patients With Refractory Chronic Lymphocytic LeukemiaCompletedNCT00431873Phase 2
- MGCD0103 in Elderly Patients With Previously Untreated AML/High Risk MDS or Adults With Relapsed/Refractory DiseaseTerminatedNCT00374296Phase 2
- A Phase I/II Study of MGCD0103 (MG-0103) in Combination With GemcitabineCompletedNCT00372437Phase 1/2
- Study of MGCD0103 Given Three Times Weekly in Patients With Relapsed and Refractory LymphomaCompletedNCT00359086Phase 2
- Study of MGCD0103 (MG-0103) in Patients With Relapsed or Refractory Hodgkin's LymphomaTerminatedNCT00358982Phase 2
- A Phase I/II Study of MGCD0103 With Azacitidine in Patients With High-Risk Myelodysplastic Syndrome (MDS) or Acute Myelogenous LeukemiaCompletedNCT00324220Phase 1/2
- A Phase I Study of MGCD0103 Given Twice Weekly in Patients With Leukemia or Myelodysplastic SyndromesCompletedNCT00324194Phase 1
- A Phase I Study of MGCD0103 Given Three-Times Weekly In Patients With Leukemia Or Myelodysplastic SyndromesCompletedNCT00324129Phase 1
- Study of MGCD0103 Given Three-Times Weekly in Patients With Advanced Solid Tumors or Non-Hodgkin's LymphomaCompletedNCT00323934Phase 1